Dicot's strategy is to build broad patent protection for the company's current and future product candidates.

Dicot has two patent families for libiguins, one of which includes natural and synthetic libiguins, the natural sources of plants, the use of libiguins for the treatment of sexual dysfunctions, and preparations for the administration of libiguins to patients. The other involves processes for the semi-synthetic production of libiguins. Dicot's patent strategy is global and covers markets that are considered clinically and commercially relevant to the product pipeline.

Contact us

Dicot AB
Dag Hammarskjölds Väg 30
SE-752 37 Uppsala SWEDEN
+46 (0) 70-663 60 09

The information is processed according to our privacy policy.